An interventional study of Balloon Brachytherapy and 3D Conformal External Beam Irradiation in Breast Cancer Female, sponsored by Sentara Norfolk General Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Sentara Norfolk General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Breast cancer patients at Sentara RMH Hahn Cancer Center who are treated with accelerated partial breast irradiation will be monitored over a period of 10 years. From this group of patients, local and regional recurrence rates will be determined. Patients in the registry will also take part in assessments of cosmesis and quality of life.
Studies have shown that giving radiation therapy to the breast after lumpectomy helps keep cancer from coming back in the breast. The purpose of this study is to see if partial breast irradiation (PBI) at SRMH Hahn Cancer Center is as good as partial breast irradiation performed in other centers in the United States in keeping cancer from coming back in the breast. Whole breast irradiation (WBI) is a standard treatment after a lumpectomy. WBI is radiation therapy given 5 days a week for 5 to 7 weeks to the whole breast. PBI is a new method of delivering radiation only to the area of the breast where the cancer was removed. PBI is given 2 times a day for 5 days. PBI may be given over a period of 5 to 10 days. This newer treatment is currently being compared with WBI in a randomized trial. Thus far, patients at low risk for cancer recurrence who have been treated with PBI have had excellent outcomes at 5 years post-treatment, but we will not know for sure if PBI is as good as WBI until the results of the randomized trial are available. However, PBI is commonly being offered outside of clinical trials in many community hospitals throughout the country. As radiation oncologists at Sentara RMH Hahn Cancer Center, we wanted to offer patients in our community the same opportunity to have this treatment, but also wanted to ensure close follow-up of all patients treated with this method, to be sure our results are similar to those of patients reported in our professional literature. There are two different methods of PBI that are being used at SRMH Hahn Cancer Center: Balloon brachytherapy and 3-D conformal external beam irradiation. This study will learn about the good and bad effects of radiation therapy. The study also will learn about the feelings women have about how their breast looks after surgery and radiation therapy.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 139 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Sentara Norfolk General Hospital is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria: Men are not eligible for this study. Women with one or more of the following conditions are ineligible for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
Device: Balloon Brachytherapy · Radiation: 3D Conformal External Beam Irradiation
The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
Number of Participants with Local and Regional Recurrence after Partial Breast Irradiation as assessed by change in Physical Exam, Mammography, MRI, Scintimammography, Biopsy, and/or Surgical Pathology.
At the time of analysis, recurrence rates in the study group will be compared to recurrence rates in stage 1 breast cancer patients with similar risk factors from the national studies of APBI and whole breast radiation therapy, to determine if SRMH recurrence rates are significantly different.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years Post RT
Number of Participants with Certain Characteristics or Risk Factors in SRMH Population that are Associated with a Higher Risk for Recurrence when Using Partial Breast Irradiation as Assessed by History and Physical, Mammography, Pathology.
At the time of analysis, it will also be determined whether these characteristics or risk factors in SRMH population are associated with a higher risk for recurrence when using this technique.
Time frame: prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/0 years post RT
Number of Participants will have Cosmetic Results Assessed by Utilizing the Breast Cancer Treatment Outcome Scale (BCTOS) using Patient Self Reports and a Cosmetic Evaluation Will Be Made by the Radiation Oncologist (or Surgeon).
The patients will be monitored for cosmesis. Physician-generated versus patient-generated ratings will be compared to characterize the evaluation of cosmetic outcome from multiple perspectives. The Radiation Oncologist (or Surgeon) will utilize criteria established in previous RTOG trials.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years post RT
Number of Participants will have Quality of Life Results Assessed by Utilizing the Breast Cancer Treatment Outcome Scale (BCTOS) using Patient Self Reports for Global Quality of Life.
The Breast Cancer Treatment Outcome Scale ( BCTOS) will be used as a primary measure to assess breast-related symptoms and treatment effects. Questionnaires will be used from the current RTOG trial of PBI vs. WBI to assess these measures using Patient Self Reports for Global Quality of Life. In evaluating the difference between the treated and untreated breast and area, the patient will select from none (assigned a value of 1, slight (assigned a value of 2), moderate (assigned a value of 3), and large (assigned a value of 4). Higher value indicates a larger difference between treated and untreated breast and area, which would be considered a worse outcome.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years
Number of Participants will have Fatigue Results Assessed by Utilizing the Breast Cancer Treatment Outcome Score (BCTOS) using Patient Self Reports.
The Medical Outcomes Study Short Form-36 ( MOS SF-36 Vitality Scale), a widely used measure with high reliability and validity, will assess fatigue. The patient will select how much of the time during the past four weeks did she feel full of life, have a lot of energy, feel worn out, and feel tired. There are five values that include all the time (assigned a value of 1), most of the time (assigned a value of 2), some of the time (assigned a value of 3), a little of the time (assigned a value of 4), and none of the time (assigned a value of 5). Full of life and have a lot of energy,a low number would be the better outcome and feel worn out and feel tired, higher number would be the better outcome.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years.
Number of Participants will have Treatment Related Symptoms Assessed by Utilizing the Breast Cancer Treatment Outcome Scale (BCTOS) using Patient Self Reports.
The Breast Cancer Treatment Outcome Score ( BCTOS) has been augumented with a brief set of additional items that focus specifically on radiotherapy-relevant symptoms (e.g., reports of skin problems, tenderness in the breast, hardness in the breast due to enhanced fibrosis, and pain). These questions relate to how much the patient has been bothered by these radiotherapy-relevant symptoms in the past four weeks. The patient will select from not bothered at all (assigned a score of 0), a little bit bothered (assigned a score of 1), somewhat bothered (assigned a score of 2), bothered quite a bit (assigned a score of 3), and bothered very much (assigned a score of 4.) The total value range is 0-92. Higher value indicates worse outcome.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years
Number of Participants will have Convenience of Care Assessed by Utilizing the Breast Cancer Treatment Outcome Scale (BCTOS) using Patient Self Reports
The Convenience of Care scale includes several items designed to assess how disruptive the treatment is on the patients' daily activities and life styles, as well as how satisfied the patients are with the duration of their treatment. By circling one number on a scale from 0 (not at all bothered) up to 10 (bothered quite a lot. Total value range is 0-80. The higher the value, the worse the outcome. The patient will evaluate her satisfaction about the treatment and results by selecting the phrase that best describes her satisfaction from totally satisfied (assigned a value of 1, somewhat satisfied (assigned a value of 2), neither satisfied or dissatisfied (assigned a value of 3), somewhat dissatisfied (assigned a value of 4), and totally dissatisfied (assigned a value of 5). The higher the value, the worse the outcome.
Time frame: Prior to radiation, 4 weeks post RT, 6 months post RT, then yearly up to 10 1/2 years
Plan to share: No
Started Mar 2009 (actual). Primary completion is estimated for Dec 2025, 201 months after the start.
Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 201 months is above that.
Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sentara Norfolk General Hospital